Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
The research firm downgraded the biotechnology stock to sell from neutral.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.